
## CLAIMS

1. A composition comprising:

(i) the random copolymer GAS914 having the following structure:




wherein n represents the average degree of polymerization, x represents the fraction of glycosylated monomer; and 1 – x represents the fraction of thioglycerol-capped monomer, and

(ii) an antibiotic.

2. The composition according to claim 1, wherein said antibiotic in (ii) is selected from the group consisting of carbapenems, cephalosporins, monobactams, penicillins, polypeptides, quinolones, sulfonamides, and tetracyclines.

3. The composition according to claims 1 or 2, for use in medicine.

4. Use of a composition according to claims 1 or 2, in the manufacture of a medicament, for the prevention and/or treatment of infection caused by bacteria of the gastrointestinal tract in a subject.

5. The use according to claim 4, wherein the infection occurs in blood, heart, cardiovascular system, liver, lung, respiratory tract, kidney, urinary tract, nervous central system, skin, subcutaneous tissues and surgical wounds.

6. The use according to claims 4 or 5, wherein the composition is to be administered to the subject subcutaneously or intravenously.

7. The use according to any one of claims 4 to 6, wherein the infection is a blood infection.

8. The use according to any one of claims 4 to 7, wherein the bacteria of the gastrointestinal tract are enteric bacteria, preferably wherein the enteric bacteria are selected from the group consisting of bacteria of the genus *Acinetobacter, Actinomyces, Bacteroides, Bifidobacterium, Campylobacter, Corynebacterium, Enterococcus, Eubacterium, Fusobacterium, Haemophilus, Helicobacter, Lactobacilus, Mobiluncus, Peptostreptococcus, Porphyromonas, Prevotella, Propionibacterium, Pseudomonas, Staphylococcus, Streptococcus* and *Veillonella*, and bacteria of the Enterobacteriaceae family.

9. The use according to claim 8, wherein the enteric bacteria of the Enterobacteriaceae family are selected from the group consisting of bacteria of the genus *Citrobacter*, *Enterobacter*, *Escherichia*, *Klebsiella*, *Proteus*, *Salmonella*, *Serratia*, *Shigella* and *Yersinia*.

10. The use according to any one of claims 4 to 9, wherein the subject has endogenous anti-Gal antibodies.

11. The use according to any one of claims 4 to 10, wherein the subject is a human.